Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
97 tokens/sec
GPT-4o
53 tokens/sec
Gemini 2.5 Pro Pro
43 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
47 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Multi-View Graph Convolutional Network and Its Applications on Neuroimage Analysis for Parkinson's Disease (1805.08801v4)

Published 22 May 2018 in cs.CV

Abstract: Parkinson's Disease (PD) is one of the most prevalent neurodegenerative diseases that affects tens of millions of Americans. PD is highly progressive and heterogeneous. Quite a few studies have been conducted in recent years on predictive or disease progression modeling of PD using clinical and biomarkers data. Neuroimaging, as another important information source for neurodegenerative disease, has also arisen considerable interests from the PD community. In this paper, we propose a deep learning method based on Graph Convolutional Networks (GCN) for fusing multiple modalities of brain images in relationship prediction which is useful for distinguishing PD cases from controls. On Parkinson's Progression Markers Initiative (PPMI) cohort, our approach achieved $0.9537\pm 0.0587$ AUC, compared with $0.6443\pm 0.0223$ AUC achieved by traditional approaches such as PCA.

User Edit Pencil Streamline Icon: https://streamlinehq.com
Authors (6)
  1. Xi Sheryl Zhang (12 papers)
  2. Lifang He (98 papers)
  3. Kun Chen (103 papers)
  4. Yuan Luo (127 papers)
  5. Jiayu Zhou (70 papers)
  6. Fei Wang (574 papers)
Citations (82)

Summary

  • The paper introduces an innovative MVGCN framework that integrates multi-modal brain graphs to diagnose Parkinson's Disease with an AUC of 0.9537.
  • It employs a pairwise learning strategy and nonlinear feature extraction to effectively model complex connectivity patterns from MRI and DTI data.
  • The integration of structural and diffusion imaging significantly outperforms traditional methods, underscoring the model’s potential for precision diagnostics.

Multi-View Graph Convolutional Network and Its Applications on Neuroimage Analysis for Parkinson's Disease

This paper explores the application of a Multi-View Graph Convolutional Network (MVGCN) to neuroimage analysis to aid in diagnosing Parkinson's Disease (PD). PD is a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons, leading to motor symptoms such as bradykinesia, rigidity, and tremor. The research prioritizes the integration of multiple neuroimaging modalities, with a particular focus on the connectivity and structural brain graphs derived from techniques like MRI and DTI, to enhance the accuracy and effectiveness of disease profiling.

The authors propose an MVGCN framework that leverages the graph-structured data from distinct imaging modalities. The essential steps of this approach include the construction of a Brain Geometry Graph (BGG) based on anatomical regions and Brain Connectivity Graphs (BCGs) derived from various tractography methods. By conveying this diverse neuroimaging data into a graph convolutional network framework, the method achieves a profound representation of the multi-modal brain structure, which is crucial for discerning between PD afflictions and control subjects.

Key Findings and Numerical Results

One of the most notable outcomes of this research is the impressive classification performance of the proposed MVGCN approach. Deploying this methodology on the Parkinson's Progression Markers Initiative (PPMI) dataset, the MVGCN demonstrates a significant Area Under the Curve (AUC) of 0.9537 ± 0.0587, greatly surpassing traditional techniques such as PCA, which reported an AUC of 0.6443 ± 0.0223. This stark contrast underscores the effectiveness of utilizing multi-modal brain imaging data through an advanced graph-based framework in enhancing discrimination accuracy in PD analysis.

Methodological Insights

The MVGCN approach undertakes several innovative processes that fortify its predictive capability:

  • Pairwise Learning Strategy: The paper highlights a transition from traditional sample-level classification to learning pairwise relationships, expanding the training dataset's variety and quantity by treating each sample pair as an input. This enhances the deep learning framework's capability in handling large-scale datasets.
  • Nonlinear Feature Learning: Conventional approaches employed in neuroimaging often rely on linear or multilinear methodologies that may not capture the richness inherent in brain imaging data. The adoption of GCN under MVGCN facilitates modeling complex nonlinear relationships inherently present in neuroimages.
  • Multi-Graph Fusion: By integrating spatial information from structural MRI with connectivity features from different DTI modalities, the approach exploits complementary information across diverse imaging modalities, vastly enriching the learned feature spaces.

Implications and Future Directions

The implications of this work are multifaceted, extending both theoretically, by providing a robust graph-based learning framework, and practically, by arming clinicians with a superior tool for PD diagnosis. The prospect of integrating multi-modal data into a unified predictive model for neurodegenerative diseases may lead to advancements in personalization and precision medicine.

Despite its strengths, the research acknowledges the current system's data-driven nature and suggests future work to include clinical domain knowledge, such as electronic health records, to further refine the model's applicability and reliability in real-world settings.

Conclusion

This paper presents a compelling case for using multi-view graph convolutional networks in neuroimage analysis, establishing a substantial leap in processing complex neuroimaging data for PD diagnosis. The MVGCN's framework not only elevates the performance metrics compared to traditional models but also offers a robust, interpretable approach towards understanding brain pathophysiology through graph-based learning. Future work should focus on integrating clinical insights and expanding the modalities further to ensure the framework's generalizability across other neurodegenerative conditions.